cbdMD, Inc. Share Price

YCBD

US12482W4087

Pharmaceuticals

Market Closed - NYSE Other stock markets 21:00:00 23/07/2026 BST			5-day change	1st Jan Change
0.5763 ^USD	+0.05%		-6.60%	-57.31%

07-14	CbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina	CI
07-14	CbdMD Expands Oasis Beverage Distribution to South Carolina	MT

Last Transcript: cbdMD, Inc.

CbdMD, Inc., Q2 2026 Earnings Call, May 14, 2026

05-14

More transcripts

Analysts' recommendations: cbdMD, Inc.

05/10/23	Maxim Starts Coverage on cbdMD with Buy Rating, $3 Price Target	MT
18/06/21	CBDMD : Cantor Fitzgerald Adjusts Price Target for cbdMD to $3.25 from $4.10, Maintains Neutral Rating	MT

More recommendations

Managers and Directors: cbdMD, Inc.

Manager	Title	Age	Since
T. Kennedy CEO	Chief Executive Officer	47	28/02/2023
Zeb Booker CTO	Chief Tech/Sci/R&D Officer	-	31/12/2018
Sibyl Swift CTO	Chief Tech/Sci/R&D Officer	45	-

Director	Title	Age	Since
Bakari Sellers BRD	Director/Board Member	41	28/02/2017
William Raines BRD	Director/Board Member	66	18/04/2019
Scott Stephen CHM	Chairman	60	02/06/2022

More insiders

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
23/07/26	US$0.5763	+0.05%	110,658
22/07/26	US$0.5760	+0.56%	78,587
21/07/26	US$0.5728	+0.58%	35,791
20/07/26	US$0.5695	-0.07%	154,530
17/07/26	US$0.5699	-7.63%	231,770

Delayed Quote NYSE

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.5763USD

Average target price

2.000USD

Spread / Average Target

+247.04%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Cap	6.05M 5.32M 4.94M 4.55M 8.53M 586M 8.68M 59.11M 23.06M 286M 22.71M 22.22M 991M	P/E 2026 *	-3.03x	P/E 2027 *	-8.23x
Enterprise Value	6.05M 5.32M 4.94M 4.55M 8.53M 586M 8.68M 59.11M 23.06M 286M 22.71M 22.22M 991M	EV / Sales 2026 *	0.27x	EV / Sales 2027 *	0.26x
Free-Float	89.32%	Yield 2026 *	-	Yield 2027 *	-

07-14	CbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina	CI
07-14	CbdMD Expands Oasis Beverage Distribution to South Carolina	MT
07-07	Cbdmd Completes Self-Affirmed Gras Determination for Broad Spectrum Cbd	CI
07-01	CbdMD Launches Oasis Mixer, A Hemp-Derived Zero-Proof THC Spirit	CI
06-16	CbdMD, Inc. Appoints Wade Brown as Chief Marketing Officer	CI
05-14	CbdMD, Inc., Q2 2026 Earnings Call, May 14, 2026
05-14	CbdMD reports 19% year-over-year and 12% sequential revenue growth	RE
05-14	CbdMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
04-06	Hawkeye Systems, Inc. Announces President and Directorate Appointments	CI
04-01	CbdMD, Inc. Announces Launch of Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare	CI
02-17	CbdMD, Inc., Q1 2026 Earnings Call, Feb 17, 2026
02-17	CbdMD, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
02-02	Cbdmd, Inc.'S Herbal Oasis Expands into Louisiana with Morales Beverage Group Following Strong Texas Momentum	CI

07-14	CbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina	PR
07-09	CbdMD's Bluebird Botanicals Announces Official Partnership With Denver Audubon to Support Bird Conservation	PR
07-07	CbdMD Sets a New Safety Standard for Broad Spectrum CBD With Self-Affirmed GRAS Determination	PR
07-01	Oasis Launches Hemp-Derived Mixer	PR
06-25	CbdMD Welcomes White House Call for Fair Treatment of Hemp-Derived Products	PR

1 day	+0.05%
1 week	-6.60%
Current month	-14.37%
1 month	-13.47%
3 months	-42.94%
6 months	-32.11%
Current year	-57.31%

1 week	0.55	0.59
1 month	0.55	0.82
Current year	0.55	1.34
1 year	0.47	2.56
3 years	0.47	13.84
5 years	0.47	964.8
10 years	0.47	2,606.4

cbdMD, Inc. Share Price

Stocks

YCBD

US12482W4087

Pharmaceuticals

Valuation: cbdMD, Inc.

Chart: cbdMD, Inc.

Latest news : cbdMD, Inc.

Last Transcript: cbdMD, Inc.

Analysts' recommendations: cbdMD, Inc.

Press Releases: cbdMD, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: cbdMD, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
14/04/26	Sibyl Swift	Free	Chief Technology Officer	1,572	0.0150%
14/04/26	Jeffrey Porter	Free	Director	1,572	0.0150%
14/04/26	William Raines	Free	Director	1,572	0.0150%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CBDMD, INC.	+0.05%	-6.60%	-39.34%	-95.03%	6.05M
ELI LILLY AND COMPANY	+1.97%	+1.43%	+48.44%	+156.66%	1,057B
JOHNSON & JOHNSON	+1.42%	+3.72%	+53.32%	+52.34%	624B
ABBVIE INC.	+1.43%	+0.99%	+34.83%	+78.74%	454B
ROCHE HOLDING AG	+0.16%	+4.88%	+32.21%	+28.15%	341B
NOVARTIS AG	-1.04%	+1.23%	+35.29%	+39.36%	297B
ASTRAZENECA PLC	-0.84%	+0.14%	+15.64%	+16.99%	262B
NOVO NORDISK A/S	-0.44%	-3.21%	-28.58%	-41.95%	215B
AMGEN INC.	+1.49%	-0.02%	+20.14%	+58.21%	201B
GILEAD SCIENCES, INC.	+0.40%	-3.99%	+15.23%	+62.28%	162B
Average	-0.20%	+0.04%	+18.72%	+35.58%	361.4B
Weighted average by Cap.	-0.53%	+1.57%	+34.93%	+75.42%

	2026 *	2027 *
Net sales	22.15M 19.48M 18.1M 16.65M 31.22M 2.15B 31.78M 216M 84.42M 1.05B 83.17M 81.37M 3.63B	23.26M 20.46M 19.01M 17.48M 32.78M 2.25B 33.37M 227M 88.65M 1.1B 87.33M 85.44M 3.81B
Net income	-1.9M -1.67M -1.55M -1.43M -2.68M -184M -2.73M -18.58M -7.25M -89.84M -7.14M -6.99M -312M	-902K -793K -737K -678K -1.27M -87.35M -1.29M -8.81M -3.44M -42.61M -3.39M -3.31M -148M
Net Debt	-	-